Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 231 to 240 of 1100 total matches.
Ramelteon (Rozerem) for Insomnia
The Medical Letter on Drugs and Therapeutics • Nov 07, 2005 (Issue 1221)
.
with chronic insomnia (405)
Data from manufacturer
10
Randomized, double-blind; Ramelteon 8 or 16 mg ...
Ramelteon (Rozerem - Takeda), a melatonin receptor agonist, has been approved by the FDA for treatment of insomnia characterized by difficulty falling asleep. Unlike all other prescription hypnotics, which are classified as schedule IV drugs, ramelteon is not a controlled substance.
Cardiovascular Effects of Some Antidiabetic Drugs
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017 (Issue 1527)
cardiovascular outcomes data are not
available to date for albiglutide (Tanzeum), dulaglutide
(Trulicity ...
...
Platelet-Derived Growth Factor for Diabetic Ulcers
The Medical Letter on Drugs and Therapeutics • Jul 17, 1998 (Issue 1031)
, but it is expensive, and published
data are sparse.
THE MEDICAL LETTER (ISSN 1523-2859) is published and printed ...
Becaplermin (be kap' ler min; Regranex - Ortho-McNeil), a 0.01% topical gel formulation of recombinant human platelet-derived growth factor (rhPDGF), was recently approved by the FDA for adjunctive treatment of diabetic ulcers of the lower extremities that extend subcutaneously or beyond and have an adequate blood supply. Endogenous platelet-derived growth factor increases proliferation of cells that repair wounds and form granulation tissue.
In Brief: Cardiovascular Safety of Varenicline (Chantix)
The Medical Letter on Drugs and Therapeutics • Aug 22, 2011 (Issue 1371)
%) of 3308 taking placebo. This difference was
statistically significant.4
Until more data become available ...
Varenicline (Chantix), which has been associated with neuropsychiatric symptoms such as agitation, depressed mood, changes in behavior and suicidal ideation, appears to be the most effective drug available for treatment of tobacco dependence.1 Recently, the FDA warned that varenicline may also increase the risk of cardiovascular adverse events in patients with cardiovascular disease.2 This warning was based on the results of a 12-week randomized trial in 714 smokers with stable cardiovascular disease. The drug was effective in helping patients stop smoking; long-term quit rates (at 52 weeks)...
In Brief: Propofol Revisited
The Medical Letter on Drugs and Therapeutics • Oct 17, 2011 (Issue 1375)
.
The mortality rate associated with brief use of propofol
is so low that few data are available comparing ...
A reader has asked us to review the use of propofol (Diprivan, and others) as a sedative agent for brief procedures, such as colonoscopy.First marketed more than 20 years ago,1 propofol has a rapid onset of action (patients usually lose consciousness in less then one minute) and a short duration of action with a rapid recovery (3-5 minutes) that makes it highly suitable for brief ambulatory procedures. Propofol is now the most commonly used parenteral anesthetic in the US.2 The main problems with its use have been pain on injection and bacterial contamination, both related to its lipid...
In Brief: Icatibant (Firazyr) for Hereditary Angioedema
The Medical Letter on Drugs and Therapeutics • Nov 28, 2011 (Issue 1378)
:581.
4. Cost of a single dose according to most recent data (October
2011) from retail pharmacies ...
The FDA has approved icatibant (Firazyr – Shire), a selective bradykinin B2 receptor antagonist, for treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare autosomal dominant disorder (estimated prevalence 1:10,000-50,000) in which patients experience recurrent and frequently unpredictable attacks of angioedema lasting 2-5 days, typically involving the extremities, gastrointestinal tract, genitalia, face, oropharynx or larynx. Laryngeal edema may be life-threatening. HAE is usually caused by a mutation of the C1-inhibitor (C1-INH) gene. C1-INH is a serine proteinase...
In Brief: New Benzodiazepine Warnings
The Medical Letter on Drugs and Therapeutics • Nov 02, 2020 (Issue 1610)
controlled substances.
Postmarketing data and published literature have
shown an increasing rate ...
The FDA now requires boxed warnings in the package
inserts of benzodiazepines describing the potential for
these drugs to be abused and misused and to cause
addiction and physical dependence. Benzodiazepine
labels have contained a boxed warning about a risk of
serious drug interactions with opioids since 2016.
In Brief: Johnson & Johnson COVID-19 Vaccine Suspended (online only)
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
Practices
(ACIP) recommended continuing the suspension until
more data become available. About 7 million ...
On April 13, 2021, the FDA and CDC advised suspending
use of the Johnson & Johnson adenovirus-based
COVID-19 vaccine while the agencies investigate 6
cases of cerebral venous sinus thrombosis (CVST) and
thrombocytopenia that occurred following administration
of the vaccine. In an April 14 emergency meeting,
the Advisory Committee on Immunization Practices
(ACIP) recommended continuing the suspension until
more data become available. About 7 million people in
the US have received the Johnson & Johnson vaccine.
COVID Update: Bivalent Vaccine Booster Doses Authorized for Children ≥5 Years Old (online only)
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
are no longer
authorized for use as booster doses in any age group.1
No data on use of the bivalent vaccines ...
The FDA has expanded its Emergency Use
Authorizations (EUAs) for the COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) to permit use of the bivalent
formulations of these products (containing mRNA
from the original and BA.4/5 Omicron strains of
SARS-CoV-2) as a booster dose in children as young
as 5 years old (Pfizer) or 6 years old (Moderna).
The bivalent Pfizer vaccine had previously been
authorized for use in persons ≥12 years old and the
bivalent Moderna vaccine in persons ≥18 years old. Bivalent vaccines are not authorized for...
Fluconazole
The Medical Letter on Drugs and Therapeutics • May 18, 1990 (Issue 818)
esophageal
candidiasis, but the clinical response was faster with fluconazole. Available data are inadequate ...
Fluconazole (Diflucan - Roerig), an antifungal azole, was recently approved by the US Food and Drug Administration for oral and intravenous (IV) treatment of cryptococcal meningitis and various forms of candidiasis. Both cryptococcal meningitis and candidiasis occur frequently in patients with AIDS, organ transplants, or cancer.